<!DOCTYPE html>
<html lang="en" dir="ltr">

<head>
  <title>IgAN Patient Case - Discover Mark's Kidney Disease Journey</title>
  <meta name="description" content="Learn about Mark’s journey with IgAN, a progressive kidney disease, and how certain kidney lesions can influence his risk of disease progression">
  {{> ../templates/header }}
  <link href="../styles.bundle.css" rel="stylesheet" type="text/css">
</head>

<body>
  <!-- Google Tag Manager (noscript) -->
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WZLFQZR3" height="0" width="0"
      style="display:none;visibility:hidden"></iframe></noscript>
  <!-- End Google Tag Manager (noscript) -->
  <main class="wrapper" data-page-id="pat-profile-mark" data-path-level="2">

    {{> ../templates/nav }}
    {{> ../templates/interstitial }}

    <div class="progress-dots-container"></div>

    {{> ../templates/mestc-score-modal }}

    <div class="modal" data-modal-id="igan-prediction">
      <div class="modal-inner">
        <img src="./assets/images/modal-close.svg" class="modal-close update-path" alt="Close X icon" />

        <h1 class="modal-big-header">International IgAN Prediction Tool<sup>1,2</sup></h1>
        <h2 class="modal-header">The International IgAN Prediction Tool was developed to help nephrologists determine
          their patients&rsquo; risk of progression to ESKD or 50% decline in eGFR</h2>

        <p class="bold purple">Factors used to determine risk:</p>

        <ul class="bullet-list">
          <li><span class="bullet">&bull;</span><span>age</span></li>
          <li><span class="bullet">&bull;</span><span>race</span></li>
          <li><span class="bullet">&bull;</span><span>eGFR</span></li>
          <li><span class="bullet">&bull;</span><span>blood pressure</span></li>
          <li><span class="bullet">&bull;</span><span>proteinuria</span></li>
          <li><span class="bullet">&bull;</span><span>presence of MEST lesions</span></li>
          <li><span class="bullet">&bull;</span><span>ACE inhibitor or ARB use</span></li>
          <li><span class="bullet">&bull;</span><span>immunosuppression use</span></li>
        </ul>

        <p class="text">Although crescents have been shown to increase risk of IgAN progression, they are not included
          in the Prediction <span class="nowrap">Tool.<sup>1-3</sup></span></p>
        <p class="text">To fully appreciate a patient&rsquo;s risk, HCPs may need to account for additional disease
          features, such as the presence of crescents.</p>

        <p class="bold purple">Continue to learn how crescents can impact IgAN progression</p>

        <div class="footnotes">
          <p>ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; HCP, healthcare provider; MEST, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T).</p>
          <p><span class="bold">References: 1.</span> Barbour SJ, et al. <em>JAMA Intern Med</em>. 2019;179(7):942-952.
            <span class="bold">2.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172. <span
              class="bold">3.</span> Du Y, et al. <em>Front Med (Lausanne)</em>. 2022;9:864667.</p>
        </div>
      </div>
    </div>

    <img id="scroll-arrow" class="update-path" src="./assets/images/scroll-arrow.svg" alt="Scroll arrow down" />

    <div id="mark-bio-tray" class="mobile-bio-tray">
      <div id="tray-close">
        <p>Baseline Assessment at Biopsy</p>
        <img src="./assets/images/back-arrow.svg" class="update-path arrow" alt="Back arrow"/>
      </div>

      <p class="name">Mark, 34</p>

      {{> ../templates/mark-bio }}

      <div class="extra-section">
        <p class="extra-footnote">*Image source: Luis Fernando Arias-Restrepo, MD, Universidad de Antioquia, Medellín, Colombia. Available from: <a class="format-url link-color" target="_blank"
          href="https://kidneypathology.com/English_version/IgA_Nephropathy.html">https://kidneypathology.com/English_version/IgA_Nephropathy.html</a>. Used with permission.
        </p>
    
        <p class="extra-footnote">ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; H&E, hematoxylin and eosin; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C).</p>
      </div>
    </div>

    <!-- //////////////////// SECTION 1 ///////////////////// -->

    <section class="" data-section-id="1" data-section-name="Mark Patient Information" data-dot-label="Meet Mark">
      <div class="two-column">

        <div id="left-bio">
          <img src="./assets/images/profiles/mark-profile.png" class="update-path bio-pic" alt="" />
          
          {{> ../templates/mark-bio }}
        </div>

        <div class="right-side">
          <img src="./assets/images/profiles/mark-profile.png" class="update-path bio-pic conditional-render" alt=""/>
          <p class="name conditional-render">Mark, 34</p>

          <h1 class="sect-1-header">Mark is a 34-year-old avid runner who travels<br class="desktop-only" /> frequently for his new position
            at work.</h1>

          <p class="bold">Over the past 2 weeks, Mark has occasionally noticed his urine had blood in it and <span
              class="nowrap">was frothy.</span></p>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Blood tests revealed his creatinine was elevated at <span class="nowrap">1.7
                mg/dL</span></span></li>
            <li><span class="bullet">&bull;</span><span>Mark was referred to a nephrologist, where additional tests
                revealed he had a proteinuria level of <span class="nowrap">2.5 g/d</span> and stage 3a CKD</span></li>
          </ul>

          <div class="divider"></div>

          <h4 class="purple align-center">Based on these results, his nephrologist performed a kidney biopsy, which confirmed IgAN, and showed
            mesangial hypercellularity, endocapillary hypercellularity, and 15% glomerular crescents.</h4>

          <p class="direction bold align-center tablet-desktop-only">Click the arrows in the carousel below to explore Carlos&rsquo; baseline characteristics</p>
        </div>

      </div>
    </section>

    <div class="temp-section mobile-only">
      <p class="direction bold align-center">Swipe in the carousel below to explore Mark&rsquo;s baseline characteristics</p>
    </div>

    <!-- //////////////////// SECTION 2 ///////////////////// -->

    <section class="" data-section-id="2" data-section-name="Mark Demographic and Information Carousel" data-dot-label="Baseline<br>Characteristics">
      <div class="owl-carousel">
        <div class="carousel-block" id="mark-block-1">
          <h3 class="label">Age at Biopsy</h3>
          <h4 class="characteristic">34 years old</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>IgAN is often diagnosed in adults aged 20-40
                years<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Clinical presentation and disease progression can vary based on
                the patient&rsquo;s age at diagnosis<sup>3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">References: 1.</span> Caster DJ, et al. <em>Kidney Int Rep</em>. 2023;8(9):1792-1800. <span
                class="bold">2.</span> Lai KN, et al. <em>Nat Rev Dis Primers</em>. 2016;2:16001. <span
                class="bold">3.</span> Gutierrez E, et al. <em>Nephrol Dial Transplant</em>. 2018;33:472-477.</p>
          </div>
        </div>

        <div class="carousel-block" id="mark-block-2">
          <h3 class="label">Race</h3>
          <h4 class="characteristic">White</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>IgAN incidence and progression can vary by region and
                ethnicity<sup>1</sup></span></li>
            <ul>
              <li><span class="bullet">&ndash;</span><span>Annual incidence in the US is ~1.29/100,000 persons,
                  compared to <span class="nowrap">~1-2/100,000</span> persons in Europe and <span class="nowrap">~4.2/100,000</span> persons in <span class="nowrap">Japan<sup>2-4</sup></span></span></li>
            </ul>
          </ul>

          <div class="footnotes">
            <p><span class="bold">References: 1.</span> Yeo SC, et al. <em>Nephrology (Carlton)</em>.
              2019;24(9):885-895. <span class="bold">2.</span> Kwon CS, et al. <em>J Health Econ Outcomes Res</em>.
              2021;8(2):36-45. <span class="bold">3.</span> Willey C, et al. <em>Nephrol Dial Transplant</em>.
              2023;38(10):2340-2349. <span class="bold">4.</span> Kiryluk K, et al. <em>Kidney360</em>.
              2023;4(8):1112-1122.</p>
          </div>
        </div>

        <div class="carousel-block" id="mark-block-3">
          <h3 class="label">Estimated GFR at Biopsy</h3>
          <h4 class="characteristic">54 mL/min/<br class="mobile-only"/>1.73 m<sup>2</sup></h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Mark&rsquo;s eGFR at biopsy indicated that he was in stage 3a
                CKD:
                some kidney damage leading to a mild to moderate loss of kidney function</span></li>
            <li><span class="bullet">&bull;</span><span>eGFR decline is a validated risk factor of IgAN progression.
                Declines in eGFR are strongly associated with the risk of CKD progression and
                mortality<sup>1,2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.</p>
            <p><span class="bold">Reference: 1.</span> Coresh J, et al. <em>JAMA</em>. 2014;311(24):2518-2531. <span class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="mark-block-4">
          <h3 class="label">Blood Pressure at Biopsy</h3>
          <h4 class="characteristic">140/80 mm Hg</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Mark&rsquo;s blood pressure was found to be elevated at
                biopsy</span></li>
            <li><span class="bullet">&bull;</span><span>Hypertension has been shown to serve as a clinical predictor of
                IgAN progression at the time of diagnosis<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Reduction of hypertension lowers the risk of progression to
                kidney failure<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">References: 1.</span> Maixnerova D, et al. <em>J Nephrol</em>. 2016;29(4):535-541.
              <span class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="mark-block-5">
          <h3 class="label">Proteinuria at Biopsy</h3>
          <h4 class="characteristic">2.5 g/d</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>Mark had elevated proteinuria at the time of biopsy</span></li>
            <li><span class="bullet">&bull;</span><span>Proteinuria is a validated prognostic marker linked to
                long-term kidney outcomes, including eGFR decline and ESKD<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>Proteinuria reduction inversely correlates with serum
                creatinine doubling, ESKD, and death<sup>2,3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.</p>
            <p><span class="bold">References: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276. <span
                class="bold">2.</span> Thompson A, et al. <em>Clin J Am Soc Nephrol</em>. 2019;14(3):469-481. <span
                class="bold">3.</span> Inker L, et al. <em>Am J Kidney Dis</em>. 2016;68(3):392-401.</p>
          </div>
        </div>

        <div class="carousel-block" id="mark-block-6">
          <h3 class="label">ACE<span class="lower">i</span>/ARB Use at the Time of Biopsy</h3>
          <h4 class="characteristic">None</h4>

          <p>While ACEi/ARBs are recommended as part of supportive care, Mark had not initiated treatment at the time of
            his biopsy.<sup>1</sup></p>

          <div class="footnotes">
            <p>ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.</p>
            <p><span class="bold">Reference: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="mark-block-7">
          <h3 class="label">MEST-C Score</h3>
          <h4 class="characteristic">M1 E1 S0 T0 C1</h4>

          <p>Mark&rsquo;s biopsy was evaluated using the Oxford classification, or MEST-C score. His biopsy showed
            mesangial hypercellularity in &gt;50% of glomeruli, endocapillary hypercellularity, and crescents in 15% of
            glomeruli, but was absent of segmental glomerulosclerosis and tubular atrophy/interstitial fibrosis.</p>
          <p>The MEST-C score can serve as a valuable early prognostic tool and should be considered when evaluating the
            risk of progression to ESKD.<sup>1-3</sup></p>

          <div class="button cta modal-trigger" data-trigger-id="mest-c-score">
            <p>Learn more about MEST-C</p>
          </div>

          <div class="footnotes">
            <p>ESKD, end-stage kidney disease; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity
              (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C).</p>
            <p><span class="bold">References: 1.</span> Cattran DC, et al. <em>Kidney Int Rep</em>.
              2023;8(12):2515-2528. <span class="bold">2.</span> Haaskjold YL, et al. <em>BMC Nephrology</em>.
              2022;23:26. <span class="bold">3.</span> Coppo R, et al. <em>Kidney Int</em>. 2014;86(4):828-836.</p>
          </div>
        </div>

        <div class="carousel-block" id="mark-block-8">
          <h3 class="label">Immunosuppression Use at or Prior to Biopsy </h3>
          <h4 class="characteristic">None</h4>

          <p>While the clinical benefits of immunosuppressive therapy have not been established in patients with IgAN,
            they may be used in specific patient populations if the risk/benefit profile is acceptable.<sup>1</sup></p>

          <div class="footnotes">
            <p><span class="bold">Reference: 1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>
      </div>

    </section>

    <div class="temp-section">
      <div class="footnotes">
        <p>*Image source: Luis Fernando Arias-Restrepo, MD, Universidad de Antioquia, Medellín, Colombia. Available from: <a class="format-url link-color" target="_blank"
          href="https://kidneypathology.com/English_version/IgA_Nephropathy.html">https://kidneypathology.com/English_version/IgA_Nephropathy.html</a>. Used with permission.
        </p>
    
        <p>ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; H&E, hematoxylin and eosin; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C).</p>
      </div>

      <img class="tablet-only update-path mobile-bio-trigger" id="mobile-bio-trigger" data-tray-id="mark-bio-tray" src="./assets/images/profiles/mobile-bio-btn.png" alt="Baseline Assessment trigger button"/>
    </div>

    <section class="" data-section-id="3" data-section-name="Mark Impact of Crescents on IgAN Progression" data-dot-label="Histopathological<br>Changes">
      <div class="flex-header">
        <img src="./assets/images/profiles/mark-profile.png" class="desktop-only update-path bio-pic" alt="" />

        <div>
          <h1 class="pat-header">Impact of Crescents<br class="desktop-only" /> on IgAN Progression</h1>
          <p class="desc-text">The International IgAN Prediction Tool indicates Mark has 12% risk of progression after 5
            years. However, his biopsy revealed crescents, which are not included in the risk prediction model but have
            been associated with poor prognosis and more rapid decline in kidney function.<sup>1-3,a</sup></p>
          <div class="gap-10"></div>
          <p class="desc-text">Given Mark&rsquo;s risk, he was started on supportive care.</p>

          <a href="https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults"
            target="_blank" class="button cta" id="sect-3-tool-exit">
            <p>View the International <br class="mobile-only"/>IgAN Prediction Tool</p>
            <img src="./assets/images/external-icon-white.svg" class="update-path" alt="External link icon" />
          </a>
          <div class="button cta modal-trigger" id="sect-3-learn-more" data-trigger-id="igan-prediction">
            <p>Learn more about the factors used to assess<br class="desktop-only" /> risk in the International IgAN
              Prediction Tool</p>
          </div>
        </div>
      </div>

      <div class="content-lower">

        <div class="divider"></div>

        <h3 class="graph-header">Changes in renal histopathological features</h3>
        <p class="direction">Use the slider to see how histopathological features can change over time and impact kidney
          survival.</p>

        <div class="images-container">
          <div class="left-side">
            <div class="text-bubble visible" id="section-3-state-1">
              <p>Mark&rsquo;s biopsy at diagnosis showed mesangial hypercellularity, endocapillary hypercellularity, and
                crescents. Crescent formation indicated by black arrow in the image below.<sup>b</sup></p>

              <div class="gap-10"></div>

              <img src="./assets/images/profiles/mark/stain.png" class="stain update-path"
                alt="PAS staining showing: Mark’s biopsy at diagnosis showed mesangial hypercellularity, endocapillary hypercellularity, and crescents. Crescent formation indicated by a black arrow." />

              <div class="gap-10"></div>

              <p>Image used with permission.*</p>
            </div>

            <div class="text-bubble" id="section-3-state-2">
              <p>Cells continue to accumulate in the capillaries and mesangium, and inflammatory cells infiltrate the
                crescent.</p>
            </div>

            <div class="text-bubble" id="section-3-state-3">
              <p>Excess ECM is deposited within the mesangium and the crescent spreads throughout the glomerulus.
                Tubules begin to show signs of atrophy.</p>
            </div>

            <div class="text-bubble" id="section-3-state-4">
              <p>Cells continue to accumulate in the capillaries and mesangium. Inflammatory cells continue to
                infiltrate the crescent, and tubular atrophy worsens.</p>
            </div>
          </div>

          <div class="right-side">
            <div class="graphic-container">
              <img src="./assets/images/profiles/mark/graphic-1.png" id="section-3-state-1" class="update-path graphic visible" 
                alt="Detailed glomerulus structure showing crescent formation, mesangial cells and immune cells" />
              <img src="./assets/images/profiles/mark/graphic-2.png" id="section-3-state-2" class="update-path graphic"
                alt="Detailed kidney structure showing crescent formation, mesangial cells and immune cells" />
              <img src="./assets/images/profiles/mark/graphic-3.png" id="section-3-state-3" class="update-path graphic"
                alt="Glomerulus showing crescent formation, mesangial cells, and immune cells" />
              <img src="./assets/images/profiles/mark/graphic-4.png" id="section-3-state-4" class="update-path graphic"
                alt="Glomerulus showing crescent formation, immune cells, and tubular atrophy" />

              <div class="histo-tag group-1" id="tag-1">
                <p>Red blood cell</p>
                <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
              <div class="histo-tag group-1" id="tag-2">
                <p>Crescent (epithelial <br class="mobile-only"/>and immune cells)</p>
                <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
              <div class="histo-tag group-1" id="tag-3">
                <p>Protein</p>
                <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
              <div class="histo-tag group-1" id="tag-4">
                <p>ECM</p>
                <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
              <div class="histo-tag group-1" id="tag-5">
                <p>Gd-IgA1 immune <br class="mobile-only"/>complexes</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
              <div class="histo-tag group-1" id="tag-6">
                <p>Immune cells</p>
                <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
              <div class="histo-tag group-1" id="tag-7">
                <p>Mesangial cells</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
              <div class="histo-tag group-3 hidden" id="tag-8">
                <p>Tubular atrophy</p>
                  <img src="./assets/images/plus-icon.svg" alt="" class="plus update-path"/>
                  <img src="./assets/images/x-icon.svg" alt="" class="close update-path"/>
              </div>
            </div>

            <div class="slider-container conditional-slider-upper">
                <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-3-state-1"
                  class="update-path slider-upper slider visible" alt="Slider shown at biopsy stage">
                <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-3-state-2"
                  class="update-path slider-upper slider" alt="Slider shown at 2 years">
                <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-3-state-3"
                  class="update-path slider-upper slider" alt="Slider shown at 4 years">
                <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-3-state-4"
                  class="update-path slider-upper slider" alt="Slider shown at 6 years">

                <input type="range" class="range-slider" id="s3-upper" name="s3-upper" min="1" max="4" value="1" step="1" />
            </div>
          </div>
        </div>

        <div class="mobile-only slider-container">
          <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-3-state-1"
            class="update-path mobile-graph slider-upper slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-3-state-2"
            class="update-path mobile-graph slider-upper slider" alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-3-state-3"
            class="update-path mobile-graph slider-upper slider" alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-3-state-4"
            class="update-path mobile-graph slider-upper slider" alt="Slider shown at 6 years">
            
          <input type="range" class="range-slider" id="s3-mobile" name="s3-mobile" min="1" max="4" value="1" step="1" />
        </div>

        <div class="slider-container conditional-slider-lower">
          <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-3-state-1"
            class="update-path slider-upper graph slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-3-state-2"
            class="update-path slider-upper graph slider" alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-3-state-3"
            class="update-path slider-upper graph slider" alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-3-state-4"
            class="update-path slider-upper graph slider" alt="Slider shown at 6 years">

          <input type="range" class="range-slider" id="s3-conditional" name="s3-conditional" min="1" max="4" value="1" step="1" />
        </div>

        <div class="graphs-container">
          <div class="left-side">
            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/mark/pro-over-time-state-1.png" id="section-3-state-1"
                class="update-path graph visible" alt="Graph modeling proteinuria progression over time, starting at biopsy">
              <img src="./assets/images/profiles/mark/pro-over-time-state-2.png" id="section-3-state-2"
                class="update-path graph" alt="Graph showing proteinuria level after two years">
              <img src="./assets/images/profiles/mark/pro-over-time-state-3.png" id="section-3-state-3"
                class="update-path graph" alt="Graph showing proteinuria progression at four years">
              <img src="./assets/images/profiles/mark/pro-over-time-state-4.png" id="section-3-state-4"
                class="update-path graph" alt="Graph showing proteinuria progression at six years">
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/mark/mobile/pro-over-time-state-1-mobile.png" id="section-3-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling proteinuria progression over time, starting at biopsy">
              <img src="./assets/images/profiles/mark/mobile/pro-over-time-state-2-mobile.png" id="section-3-state-2"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria level after two years">
              <img src="./assets/images/profiles/mark/mobile/pro-over-time-state-3-mobile.png" id="section-3-state-3"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression at four years">
              <img src="./assets/images/profiles/mark/mobile/pro-over-time-state-4-mobile.png" id="section-3-state-4"
                class="update-path mobile-graph graph" alt="Graph showing proteinuria progression at six years">
            </div>
          </div>
          <div class="right-side">
            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/mark/egfr-over-time-state-1.png" id="section-3-state-1"
                class="update-path graph visible" alt="Graph modeling eGFR decline over time, starting at biopsy">
              <img src="./assets/images/profiles/mark/egfr-over-time-state-2.png" id="section-3-state-2"
                class="update-path graph" alt="Graph showing eGFR after two years">
              <img src="./assets/images/profiles/mark/egfr-over-time-state-3.png" id="section-3-state-3"
                class="update-path graph" alt="Graph showing eGFR after four years">
              <img src="./assets/images/profiles/mark/egfr-over-time-state-4.png" id="section-3-state-4"
                class="update-path graph" alt="Graph showing eGFR after six years">
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/mark/mobile/egfr-over-time-state-1-mobile.png" id="section-3-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling eGFR decline over time, starting at biopsy">
              <img src="./assets/images/profiles/mark/mobile/egfr-over-time-state-2-mobile.png" id="section-3-state-2"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after two years">
              <img src="./assets/images/profiles/mark/mobile/egfr-over-time-state-3-mobile.png" id="section-3-state-3"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after four years">
              <img src="./assets/images/profiles/mark/mobile/egfr-over-time-state-4-mobile.png" id="section-3-state-4"
                class="update-path mobile-graph graph" alt="Graph showing eGFR after six years">
            </div>
          </div>
        </div>

        <div class="slider-container">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-3-state-1"
              class="update-path slider-lower slider visible" alt="Slider shown at biopsy stage">
            <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-3-state-2"
              class="update-path slider-lower slider" alt="Slider shown at 2 years">
            <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-3-state-3"
              class="update-path slider-lower slider" alt="Slider shown at 4 years">
            <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-3-state-4"
              class="update-path slider-lower slider" alt="Slider shown at 6 years">
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-3-state-1"
              class="update-path mobile-graph slider-lower slider visible" alt="Slider shown at biopsy stage">
            <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-3-state-2"
              class="update-path mobile-graph slider-lower slider" alt="Slider shown at 2 years">
            <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-3-state-3"
              class="update-path mobile-graph slider-lower slider" alt="Slider shown at 4 years">
            <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-3-state-4"
              class="update-path mobile-graph slider-lower slider" alt="Slider shown at 6 years">
          </div>

          <input type="range" class="range-slider" id="s3-lower" name="s3-lower" min="1" max="4" value="1" step="1" />
        </div>
      </div>

      <h4 class="bottom-subhead">Current KDIGO guidelines do not recommend SGLT2i use in IgAN in the absence of
        diabetes, as additional data are needed to assess efficacy and safety. Treatments in hypothetical patient cases
        reflect current treatment guidelines.<sup>4</sup></h4>

      <div class="footnotes">
        <p>The graphic shown above is for illustrative purposes only and is intended to educate on potential
          histopathological changes that could occur during IgAN. It is not intended to provide specific information
          about the progression of these changes or inform treatment decisions. Changes in proteinuria and eGFR are
          hypothetical and are based on trends seen in clinical trials and cohort studies.<sup>5-8</sup></p>
        <p>*Image source: Luis Fernando Arias-Restrepo, MD, Universidad de Antioquia, Medellín, Colombia. Available from: <a class="format-url link-color" target="_blank"
          href="https://kidneypathology.com/English_version/IgA_Nephropathy.html">https://kidneypathology.com/English_version/IgA_Nephropathy.html</a>. Used with permission.
        </p>
        <p><sup>a</sup>Predicted risk of progression was calculated using the International IgAN Prediction Tool and
          defined as the risk of a 50% decline in eGFR or ESKD.<sup>3</sup></p>
        <p><sup>b</sup>H&E staining showing mesangial hypercellularity, endocapillary hypercellularity, and crescent
          formation. Crescent formation indicated by black arrow. A single glomerulus may not capture all components of
          the MEST-C score.</p>
        <p>eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; H&E, hematoxylin and eosin;
          KDIGO, Kidney Disease: Improving Global Outcomes; MEST-C, mesangial hypercellularity (M), endocapillary
          hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C);
          SGLT2i, Sodium-Glucose Transport Protein 2 inhibitor.</p>
        <p><span class="bold">References: 1.</span> Pattrapornpisut P, et al. <em>Am J Kidney Dis</em>.
          2021;78(3):429-441. <span class="bold">2.</span> Cattran DC, et al. <em>Kidney Int Rep</em>.
          2023;8(12):2515-2528. <span class="bold">3.</span> Barbour SJ, et al. <em>JAMA Intern Med</em>.
          2019;179(7):942-952. <span class="bold">4.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276. <span
            class="bold">5.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>. 2023;18(6):727-738. <span
            class="bold">6.</span> Faucon AL, et al. <em>Nephrol Dial Transplant</em>. 2024;30:gfae085. <span
            class="bold">7.</span> Rovin BH, et al. <em>Lancet</em>. 2023;402(10417):2077-2090. <span class="nowrap"><span
            class="bold">8.</span> Lafayette R,</span> et al. <em>Lancet</em>. 2023;402:859-870.</p>
      </div>
    </section>

    <section data-section-id="4" class="gray-bg" data-section-name="Mark Impact of Crescents on IgAN Progression 100-month Kidney Survival Rate" data-dot-label="Impact of<br>Crescents">
      <div class="flex-header">
        <img src="./assets/images/profiles/mark-profile.png" class="desktop-only update-path bio-pic" alt="" />

        <div>
          <h1 class="pat-header">Impact of Crescents<br class="desktop-only" /> on IgAN Progression</h1>
          <p class="desc-text">The International IgAN Prediction Tool indicates Mark has 12% risk of progression after <span class="nowrap">5
            years.</span> However, his biopsy revealed crescents, which are not included in the risk prediction model but have
            been associated with poor prognosis and more rapid decline in kidney function.<sup>1-3,a</sup></p>
          <div class="gap-10"></div>
          <p class="desc-text">Given Mark&rsquo;s risk, he was started on supportive care.</p>
        </div>
      </div>

      <div id="content-box">
        <h2>The presence of crescents signals an urgent need to treat</h2>

        <div class="flex">
          <img src="./assets/images/profiles/mark/crescents-graphic.png" class="graphic update-path"
            alt="Detailed glomerulus structure showing presence of crescents" />

            <ul class="bullet-list">
              <li><span class="bullet">&bull;</span><span>Crescents indicate active glomerular inflammation from GBM rupture, leading to cell and protein accumulation in Bowman&rsquo;s space<sup>4</sup></span></li>
              <li><span class="bullet">&bull;</span><span>Early crescents may be reversible, but a high C score suggests rapid kidney failure<sup>5,6</sup></span></li>
            </ul>
        </div>

        <p class="subhead">High C scores are indicative of active glomerular injury and rapid disease progression<sup>6,7</sup></p>
      </div>

      <div class="footnotes">
        <p><sup>a</sup>Predicted risk of progression was calculated using the International IgAN Prediction Tool and defined as the risk of a 50% decline in eGFR or ESKD.</p>
        <p>eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; GBM, glomerular basement membrane; MEST-C, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy and interstitial fibrosis (T), crescent (C).</p>
        <p><span class="bold">References: 1.</span> Pattrapornpisut P, et al. <em>Am J Kidney Dis</em>. 2021;78(3):429-441. <span class="bold">2.</span> Cattran DC, et al. <em>Kidney Int Rep</em>. 2023;8(12):2515-2528. <span class="bold">3.</span> Barbour SJ, et al. <em>JAMA Intern Med</em>. 2019;179(7):942-952. <span class="bold">4.</span> Mushafi AA, et al. <em>Front Physiol</em>. 2021;12:724186. <span class="bold">5.</span> Trimarchi H, et al. <em>Kidney Int</em>. 2017;91(5):1014-1021. <span class="bold">6.</span> Shen XH, et al. <em>J Nephrol</em>. 2015;28:441-449. <span class="bold">7.</span> Rodrigues JC, et al. <em>Clin J Am Soc Nephrol</em>. 2017;12:677-686.</p>
      </div>
    </section>

    <section data-section-id="5" class="gray-bg acc-section" data-section-name="Mark Impact of eGFR Decline on Progression to ESKD" data-dot-label="Impact of eGFR<br>Decline on<br>Progression">

      <div class="acc-header">
        <p>Learn more about how Mark&rsquo;s eGFR may decline over time</p>
        <img src="./assets/images/acc-arrow.svg" class="update-path acc-arrow" alt=""/>
      </div>

      <div class="acc-content">
        <div class="flex-header">
          <img src="./assets/images/profiles/mark-profile.png" class="desktop-only update-path bio-pic" alt="" />

          <div>
            <h1 class="pat-header">Impact of eGFR Decline<br class="desktop-only" /> on Progression to Kidney Failure</h1>
            <p class="desc-text">Based on how quickly Mark&rsquo;s eGFR declines, he may reach<br class="desktop-only" />
              kidney failure within 10 years.</p>
          </div>
        </div>

        <p class="bold">If Mark&rsquo;s eGFR decline stabilizes, this can delay the onset of kidney failure.</p>
        <p class="direction">Select a button below to see how different rates of eGFR decline can impact progression to
          kidney failure.</p>

        <div class="graph-container">
          <div class="desktop-only">
            <img src="./assets/images/profiles/mark/section-5-graph-state-0.png" id="0" class="update-path graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/mark/section-5-graph-state-1.png" id="state-3" class="visible update-path graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/mark/section-5-graph-state-2.png" id="state-2" class="update-path graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/mark/section-5-graph-state-3.png" id="state-1" class="update-path graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/mark/mobile/section-5-graph-state-0-mobile.png" id="0" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/mark/mobile/section-5-graph-state-1-mobile.png" id="state-3" class="visible update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/mark/mobile/section-5-graph-state-2-mobile.png" id="state-2" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/mark/mobile/section-5-graph-state-3-mobile.png" id="state-1" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
          </div>

          <div class="hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
          <div class="hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
          <div class="hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>

          <div class="upper-hotspots">
            <div class="hotspot lower-hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>
            <div class="hotspot lower-hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
            <div class="hotspot lower-hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
          </div>
        </div>


        <div class="footnotes">
          <p>CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.</p>
        </div>
      </div>

    </section>

    <section class="switch-pat-section" data-section-name="Switch Patient">
      <h2 class="yellow-header">SELECT ANOTHER HYPOTHETICAL PATIENT</h2>

      <div class="flex">
        <div class="profile nav-el" data-nav-url="progression/sarah" data-exit-url="progression/sarah">
          <img src="./assets/images/profiles/sarah-profile.png" class="update-path" alt="Profile image for Sarah" />
          <h3>Sarah</h3>
        </div>
        <div class="profile nav-el" data-nav-url="progression/carlos" data-exit-url="progression/carlos">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path" alt="Profile image for Carlos" />
          <h3>Carlos</h3>
        </div>
      </div>

      <img src="./assets/images/or-line-graphic.png" class="or-line update-path" alt="Or" />

      <div class="button nav-el" id="discover" data-exit-url="pathogenesis/index" data-nav-url="pathogenesis/index">
        <p>Discover the pathogenesis of IgAN</p>
      </div>
    </section>

    {{> ../templates/footer-el }}

  </main>

  <script type="text/javascript" src="../static.bundle.js" charset="utf-8"></script>
</body>

</html>